Clinical Trial for PB-119 in Healthy Subjects (Phase I)

Status Completed

Clinical Trial Summary

GLP-1 analogues have been widely used because of their unique advantages (no risk of hypoglycemia) due to their glucose dependent mechanism. Due to the short half-life of peptide in plasma, peptides have to be administered frequently (i.e. BID for Byetta, with Exenatide as API).To improve the patients compliance and reduce potential adverse events associated with GLP-1 analogues, a long acting GLP-1 analogue (PB-119), which may be administered once weekly, was developed by PegBio Inc. In order to provide rational for dosage range to be studied in Phase Ib, the safety profile, tolerance, and pharmacokinetic behavior of PB-119 in healthy subjects will be studied in this randomized, controlled dose escalating trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02084251
Study type	Interventional
Source	PegBio Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	February 2014
Completion date	November 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02127762` - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy	N/A
Withdrawn	`NCT04569214` - The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients	Phase 2
Completed	`NCT01698528` - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration	N/A
Completed	`NCT00985114` - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity	N/A
Active, not recruiting	`NCT05120219` - A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers	Phase 1
Completed	`NCT04893135` - Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes	N/A
Not yet recruiting	`NCT05108350` - A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects	Phase 1
Completed	`NCT02586129` - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes	Phase 3
Completed	`NCT02914743` - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes	N/A
Completed	`NCT04540016` - Mass Balance and Biotransformation of [14C]HSK7653 in Human	Phase 1
Completed	`NCT02429258` - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin	Phase 4
Completed	`NCT01055223` - Fracture Risk With Thiazolidinediones	N/A
Terminated	`NCT02365233` - Fatty Liver Study in Patients With Type II Diabetes	Phase 4
Completed	`NCT05878587` - Burger Allen Exercises in Knee OA With Type II Diabetes	N/A
Completed	`NCT04768673` - A Study to Investigate the PK and Safety of CKD-393	Phase 1
Not yet recruiting	`NCT05028140` - Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus	Phase 3
Terminated	`NCT01804777` - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes	Early Phase 1
Completed	`NCT01619332` - Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763	Phase 1/Phase 2
Active, not recruiting	`NCT06387433` - Effectiveness of an mHealth Mobile App	N/A
Completed	`NCT01881074` - Periodontal Treatment Response in Type II Diabetic Patients